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Abstract
Background: The cardioprotective effects of glucagon-like peptide-1 (GLP-1) and analogs have been previously reported.
We tested the hypothesis that albiglutide, a novel long half-life analog of GLP-1, may protect the heart against I/R injury by
increasing carbohydrate utilization and improving cardiac energetic efficiency.
Methods/Principal Findings: Sprague-Dawley rats were treated with albiglutide and subjected to 30 min myocardial
ischemia followed by 24 h reperfusion. Left ventricle infarct size, hemodynamics, function and energetics were determined.
In addition, cardiac glucose disposal, carbohydrate metabolism and metabolic gene expression were assessed. Albiglutide
significantly reduced infarct size and concomitantly improved post-ischemic hemodynamics, cardiac function and energetic
parameters. Albiglutide markedly increased both in vivo and ex vivo cardiac glucose uptake while reducing lactate efflux.
Analysis of metabolic substrate utilization directly in the heart showed that albiglutide increased the relative carbohydrate
versus fat oxidation which in part was due to an increase in both glucose and lactate oxidation. Metabolic gene expression
analysis indicated upregulation of key glucose metabolism genes in the non-ischemic myocardium by albiglutide.
Conclusion/Significance: Albiglutide reduced myocardial infarct size and improved cardiac function and energetics
following myocardial I/R injury. The observed benefits were associated with enhanced myocardial glucose uptake and a
shift toward a more energetically favorable substrate metabolism by increasing both glucose and lactate oxidation. These
findings suggest that albiglutide may have direct therapeutic potential for improving cardiac energetics and function.
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Introduction
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted
by intestinal L-cells in response to nutrient ingestion [1]. GLP-1
occurs in a number of biologically active isoforms including full
length GLP-1 (7–36) amide, a glycine-extended isoform of GLP-1
(7–37), and the N terminus cleaved GLP-1 (9–36). GLP-1 regulates
glucose homeostasis by stimulating insulin secretion, inhibiting
glucagon secretion,delaying gastric emptying and promoting satiety
[2]. Although the major physiological function of GLP-1 is
associated with glycemic control, increasing evidence indicates that
GLP-1mayalsoplayanimportantroleincardiovascularphysiology
[3]. It has been reported that GLP-1 receptors are expressed in both
heart and coronary vasculature and activation of GLP-1 receptors
by agonists results in a wide range of cardiovascular effects such as
cardioprotection against myocardial ischemia-reperfusion injury
both ex vivo [4–7] and in vivo [5].
GLP-1 has a very short half-life of about 2 min following
exogenous administration as it is rapidly cleaved and inactivated in
plasma by the protease dipeptidyl peptidase-IV (DPP-IV). This
short half-life limits its use as a therapeutic agent. However, GLP-1
analogs that mimic the effect of GLP-1 but are resistant to DPP-IV
have been explored for the treatment of type 2 diabetes [2,8].
Despite consistent effects of GLP-1 analogs on glycemic control
observed in preclinical and clinic studies, the effect on myocardial
I/R injury remains controversial [9–11]. It is of clinical relevance
to further validate the cardioprotection and explore its novel
protective mechanism of GLP-1 analogs as these novel GLP-1
analog agents are being developed for a diabetic patient
population whom are also at high risk for cardiovascular disease.
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beneficial in protecting the heart against ischemic injury [12]. It is
well known that GLP-1 receptor activation leads to insulinotropic
and insulinomimetic effects in various tissues including the heart
[2,13–15]. In addition, a few studies have been performed in situ
[13,14] and ex vivo [6,7] to assess the beneficial effects of GLP-1 on
glucose uptake by the heart. However, the intermediary
carbohydrate metabolism and overall effect on cardiac energetics
following GLP-1 receptor activation have not been previously
described. Albiglutide consists of two copies of a 30 amino acid
sequence of human glucagon-like peptide 1 (GLP-1, fragment 7–
36) that is DPP-IV resistant (alanine to glycine conversion at
amino acid 8) fused with human albumin to provide a long half-life
of ,6–8 days [17]. Albiglutide is currently being investigated in a
phase III clinical trial for its potential to treat type II diabetes [18].
In the present study, we hypothesized that albiglutide, a novel long
half-life GLP-1 analog, may exert cardioprotective effects in a
rodent model of myocardial I/R injury by shifting cardiac energy
metabolism toward more efficient carbohydrate utilization,
thereby improving cardiac energetics and increasing cardiac
function.
Materials and Methods
Myocardial ischemia/reperfusion injury, hemodynamic
measurement and postmortem analysis in Sprague-
Dawley rats
Male Sprague-Dawley rats purchased from Charles-River
laboratory (Wilmington, DE), were used for the study. All animal
studies were performed in compliance with the Guide for the Care
and Use of Laboratory Animals as published by the US National
Institutes of Health and were approved by the Institutional Animal
Care and Use Committee of GlaxoSmithKline. Rats were treated
with vehicle or albiglutide at 1, 3 or 10 mg/kg/day (n=8–10 per
group) by daily subcutaneous injection for 3 days. The last dose
was administered 2 h before ischemia. Rats underwent 30 min
myocardial ischemia via left anterior descending artery occlusion
followed by 24 h reperfusion as previously described [19,20]. Rat
hemodynamics and myocardial infarct size were determined as
previously described [19,20]. All metabolic mechanism studies
were conducted with 3 days of dosing at 10 mg/kg/day unless
otherwise indicated.
Cardiac glucose uptake measurement in vivo and ex vivo
Cardiac glucose disposal in vivo was conducted as previously
described in conscious rats [21,22]. Briefly, rats were dosed with
albiglutide as described above prior to administration of 2-[
3H]
deoxyglucose (2-[
3H] DG) intravenously (n=14–15 per group).
Glucose disposal flux was determined using the average plasma
glucose concentration, terminal heart tissue radioactivity, and
plasma glucose radioactivity AUC (area under the curve) [21,22].
To further examine the direct role of albiglutide on cardiac
glucose disposal, dosing was performed as described above prior to
harvesting the heart and performing the Langendorff perfused
heart preparation as previously described [6,23]. The glucose flux
across the heart was determined as (concentration of glucose
(initial)2concentration (final))6(perfusion volume/heart wet
weight (g)/time (h)); Lactate flux was determined as (concentration
of lactate (final)2concentration (initial))6(perfusion volume/heart
wet weight (g)/time (h)) [6].
Cardiac metabolic flux assessment
Two separate experiments were performed to examine cardiac
intermediary metabolism: 1) relative carbohydrate vs. free fatty
acid oxidation was assessed following an in vivo glucose clamp
experiment, and 2) lactate flux and oxidation were assessed in the
Langendorff perfused heart.
For the glucose clamp experiment, rats (n=5 per group) were
treated with albiglutide as described above prior to being subjected
to a euinsulinemic-hyperglycemic clamp (continuous [1-
13C]
glucose (8 mg/kg/min)/somatostatin (1.5 mg/min) infusion via
jugular vein) under awake conditions for 120 min. The POCE
(Proton Observe Carbon Enhanced)
1H magnetic resonance
spectroscopy (MRS) measurements of metabolite
13C enrichments
in tissue extracts were performed using a 9.4T spectrometer as
previously reported [19,24–26]. Relative cardiac carbohydrate
(including glucose, glycogen, pyruvate, and lactate) and free fatty
acid (FFA)/ketone oxidation in terms of relative substrate
contribution to acetyl-CoA oxidation was assessed from the
metabolite pool enrichments as follows: the relative carbohydrate
oxidation rate was calculated as: (4-
13C glutamate enrichment)/
(3-
13C alanine enrichment), and the relative fat oxidation is
calculated as: 1-(4-
13C glutamate enrichment)/(3-
13C alanine
enrichment).
For assessing lactate oxidation and flux, a perfused heart
experiment was performed in which 3-
13C lactate was used as a
precursor for lactate oxidation measurements. Rats were treated
with albiglutide as described above prior to harvesting hearts.
Albiglutide (0.12 mM) or vehicle (n=10/group) was added to a
modified KH solution containing 3% BSA (essentially fatty acid
free), 1 mM 3-
13C sodium lactate, 0.1 mM sodium pyruvate,
0.4 mM sodium palmitate, and 11 mM glucose. The heart was
perfused for 60 minutes during which influent and effluent
samples were collected and lactate concentration was analyzed
using an Olympus AU640 analyzer. In addition, influent and
effluent 3-
13C lactate enrichments and heart tissue 3-
13C lactate,
3-
13C alanine, and 4-
13C glutamate enrichments were measured
by MRS and relative lactate oxidation as substrate contribution to
acetyl-CoA was calculated as: (4-
13C glutamate enrichment)/
(3-
13C alanine enrichment).
In vivo cardiac energetic assessment
To examine the effect of albiglutide on the cardiac energetic
profile (e.g. ATP, PCr, ATP/PCr) following cardiac I/R injury,
animals were treated with albiglutide or vehicle and then subjected
to 30 min ischemia followed by 24 hrs reperfusion as described
above. Cardiac MRI/MRS was performed at 24 hrs post-
reperfusion using a double tune (
1H,
31P) concentric surface radio
frequency (RF) coil (m2m Imaging, Newark, NJ) setup on a 9.4T/
30 cm Bruker Biospec system (Billerica, MA). A cine loop was
generated for each imaging slice through the ventricles with a
sufficient number of delays to cover the cardiac cycle. The imaging
parameters were as follows: matrix dimensions, 1286128; TR/TE,
7/1.5 ms; slice thickness, 2.0 mm; FOV, 5.0 cm; number of
repetition 250; cine loop, 10 images. Left ventricle (LV) functional
parameters were analyzed (Analyze AVW software, AnalyzeDirect,
Lenexa, KS).
31P MRS was performed immediately following the
imaging using the same RF hardware and spatially localized
spectroscopy of the heart was performed using a 3-D Image
Selected In Vivo Spectroscopy (ISIS) sequence with outer volume
suppression (TR=4 s, NS=512, SW=10 kHz, 1 k data). The
spectroscopic voxel of interest size was 15.8611617 mm and
positioned to cover the LV in an oblique plane in all three
orthogonal directions.
31P NMR spectra were processed using an
exponential filter and baseline flattening. The phosphocreatine
(PCr) peak,wassetto0 ppm,andtheinorganicphosphate (Pi) peaks
at 4.9–5.3 ppm (including both intracellular and extracellular Pi)
and the b-adenosine triphosphate (ATP) peak at 216 ppm were
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respectively (Nuts NMR processing software, Acorn NMR Inc.,
Fremont, CA). The intracellular pH was calculated using the
chemical shift difference between intracellular Pi and PCr as
previously described [27]. Absolute concentrations of ATP and PCr
were extrapolated using an external concentration standard.
Biochemical analysis, clinical chemistry and albiglutide
pharmacokinetics
Tissue cAMP was measured using an EIA kit from Cayman
Chemical (Cat#581001). Cardiac glycogen was measured as
previously described [28]. Plasma insulin was measured using
MDS rat insulin Kit (K152BZC-2). Glucose and lactate were
measured using an Olympus AU 640 analyzer (Olympus America
Inc., Melville, NY). Rat plasma samples were analyzed for
albiglutide using an analytical method based on sample dilution
followed by immunoassay analysis.
Cardiac metabolic gene expression analysis
Quantitative TaqMan reverse-transcription (RT) polymerase
chain reaction (PCR) analysis was performed on total RNAthat was
extracted from LV in a subgroup of SD rats that were treated with
vehicle or albiglutide as described above (n=8 biological replicates
and n=2 technical replicates per group). Twenty four key
metabolic, mitochondrial, and stress associated genes were assessed
in normal LV as well as ischemic and non-ischemic LV from I/R
experiment. These genes consisted of: ACSL1, CPT1B, GAPDH,
IGF1R, SLC2A4, HK2, GYS1, ESSRA, HIF1A, PPARGC1A,
PDHA1, ALDOC, GSK3B, AKT1, SLC2A1, PYGL, PRKAA2,
PPARG, HK1, PDK1, UCP2, ACTB, LDHA, UCP3. Gene
expression data was normalized using the Omics StudioH software.
One-way ANAOVA and PCA were performed thereafter.
Statistical analysis
Data are presented as mean 6 SEM. Differences between groups
were compared by paired and unpaired Student’s t tests or by a one-
way ANOVA followed by a Bonferroni test for multiple comparisons.
Apv a l u eo f,0.05 was considered statistically significant.
Results
Body weight, food consumption, and plasma levels of
insulin, glucose, lactate and albiglutide
Albiglutide significantly reduced body weight and food
consumption in a dose-dependent manner which is consistent
with the known pharmacology of GLP-1 mimetics (Table 1).
Albiglutide also increased plasma insulin and concomitantly
decreased plasma glucose compared to vehicle at all doses. Plasma
lactate was elevated at the higher doses (3 and 10 mg/kg) of
albiglutide. The terminal plasma concentrations of albiglutide
were 7.961.7 nM, 1761.8 nM and 118618.8 nM at the 1, 3 and
10 mg/kg doses, respectively (Table 1).
Myocardial infarct size, cAMP concentration, and function
following ischemia/reperfusion injury
The myocardial infarct size following I/R injury averaged
53.362.0% of the area at risk in the vehicle group after I/R
injury. Treatment with albiglutide significantly reduced infarct size
compared to vehicle: Infarct size was 45.762.4%, 39.463.7%,
and 39.562.1% of area at risk at doses of 1, 3 and 10 mg/kg,
respectively (all p,0.05, Figure 1A, B; Table 2). The area at risk
was similar between vehicle- and albiglutide-treated animals
(Figure 1C). There were no differences in heart rate or LV
systolic pressure between vehicle- and albiglutide-treated animals
(Table 2). However, the increased LV end diastolic pressure
induced by I/R injury was significantly blunted with albiglutide
(10 mg/kg) and the decreased contractile function was significant-
ly improved with albiglutide treatment (3, 10 mg/kg) compared to
vehicle (Table 2). cAMP levels in the ischemic and non-ischemic
regions of the heart were measured in a separate group of animals.
While cAMP concentrations were not elevated following albiglu-
tide treatment (10 mg/kg) in the non-ischemic LV, cAMP levels
were normalized in the ischemic region by albiglutide (Figure 1D).
Cardiac glucose disposal and intermediary metabolism
To determine if increased myocardial glucose uptake is
associated with albiglutide treatment, in vivo,[
3H]-2-deoxyglucose
uptake was determined. As shown Figure 2A, 2-DG uptake in the
heart was significantly increased by 67% following treatment with
albiglutide when compared to vehicle (p,0.05).
To further assess the direct versus indirect effects of albiglutide
on cardiac glucose uptake, ex vivo cardiac glucose disposal and
lactate flux were evaluated in the Langendorff perfused heart using
the same in vivo dosing protocol as described above and followed
by a continuous perfusion of albiglutide at 0.12 mM (equivalent to
the 10 mg/kg dose concentration in the in vivo study). The glucose
disposal was increased by 59% (p,0.05) in the albiglutide-treated
hearts compared to the vehicle treated hearts (Figure 2B).
Interestingly, lactate efflux was decreased by 55% in albiglutide-
treated hearts compared to vehicle-treated hearts (p,0.05,
Table 1. Clinical chemistry profile in rats following 3 days of albiglutide administration.
Vehicle Albiglutide (mg/kg)
13 1 0
Body weight (g) 279662 7 8 642 9 3 672 9 0 68
Body weight change (g/day) 7618 615 61 2561*
Insulin (pg/ml) 4466160 25466500* 17446491 19876418*
Glucose (mg/dL) 214651 6 6 64* 17067* 15767*
Lactate (mg/dL) 13611 4 61.7 1761.4
{ 2162.1*
Terminal albiglutide concentration (nM) — 7.961.7 1761.8 118618.8
Data are presented as mean 6 SEM, n=8–10 per group.
*p,0.01 vs. vehicle;
{p,0.05 vs.vehicle.
doi:10.1371/journal.pone.0023570.t001
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the study was also significantly lower (Q41%, p,0.05) in
albiglutide versus vehicle-treated hearts (Figure 2D).
To determine the effect of albiglutide on cardiac intermediate
glucose metabolism, metabolic substrate utilization was assessed
using a 1-
13C glucose euinsulinemic-hyperglycemic clamp. There
were no differences in alanine and lactate enrichments between
vehicle- and albiglutide-treated hearts (Figure 3A). However,
enrichment of 4-
13C glutamate, a TCA cycle intermediate, was
significantly higher in the albiglutide-treated heart compared to
vehicle-treated heart reflecting increased glycolytic flux into the
TCA cycle (Figure 3A). Furthermore, treatment with albiglutide
resulted in a significantly increased relative ratio of carbohydrate
versus fat oxidation (q112%, p,0.05 vs. vehicle) as calculated by
isotopomer analysis of alanine and glutamate enrichments
(Figure 3B). Cardiac glycogen levels were similar in both
Figure 1. Infarct size following myocardial ischemia/reperfusion injury. Sprague-Dawley rats were subjected to 30 min LAD coronary artery
occlusion followed by 24 h reperfusion. Hearts were harvested and analyzed for area at risk and infarct size. Representative photographs of heart
sections from vehicle, 1, 3, and 10 mg/kg albiglutide-treated animals stained with 2,3,5-triphenyltetrazolium chloride (TTC) and Evans blue dye
illustrate myocardial infarct (white), area at risk (white and red) and area not at risk (dark blue) (A). Myocardial infarct size was assessed as a
percentage of area at risk in the left ventricle (B). The area at risk was assessed as a percentage of the left ventricle area is shown in (C). Cardiac cAMP
was measured in both ischemic and non-ischemic areas (D). Values are presented as mean 6 SEM. *p,0.01 and
{p,0.001 vs. vehicle.
doi:10.1371/journal.pone.0023570.g001
Cardioprotection by Albiglutide
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11.463.5 mmol/g, respectively). However, albiglutide did not
alter the metabolic profile in the ischemic heart (data not shown).
To further explore the effect of albiglutide treatment on cardiac
lactate metabolism, 3-
13C lactate cardiac flux and oxidation were
assessed in the Langendorff perfused heart under physiological
conditions of substrate availability (i.e. inclusion of glucose, lactate,
pyruvate, FFA at physiological levels). Albiglutide transiently
increased lactate influx into the perfused heart over 30 min
(Figure 4A) (negative efflux) while having no effect on cardiac
lactate concentration in this experiment (Figure 4B). Yet,
albiglutide treatment resulted in an increased relative lactate
oxidation compared to vehicle (q63%, p,0.05, Figure 4C).
Metabolic gene transcription
TaqmanH RT-PCR analysis was performed using a refined
panel of 24 genes involved in regulation of glucose and fat
metabolism with both normal and I/R injured heart tissues.
ACSL1, CPT1B, GAPDH, IGF1R, SLC2A4, HK2, GYS1,
ESSRA, HIF1A, PPARGC1A, PDHA1, ALDOC, GSK3B,
AKT1 increased significantly in normal hearts following treatment
with albiglutide (Table 3). Although fewer genes (GYS1, SLC2A4)
Table 2. Infarct size, ischemic area and hemodynamics in rats following 3 days of albiglutide administration.
Vehicle Albiglutide (mg/kg)
13 1 0
Infarct size (% of area at risk) 5362.0 45.762.4 39.463.7* 39.562.1*
Area at risk (% of left ventricle) 39.762.5 4162.7 42.962.2 39.661.6
Heart rate (bpm) 408614 38669 412684 0 9 612
LVSP (mmHg) 94639 4 649 9 621 0 2 63
LVEDP (mmHg) 11611 0 611 0 618 61*
dP/dt max (mmHg/s) 59216194 61126434 70336257* 74616475
{
dP/dt min (mmHg/s) 49246297 49786395 54366224 62546537
Data are presented as mean 6 SEM, n=8–10 per group.
*p,0.01 vs. vehicle;
{p,0.05 vs. vehicle.
doi:10.1371/journal.pone.0023570.t002
Figure 2. Cardiac glucose metabolism in vivo and ex vivo. Cardiac [
3H]-2-deoxyglucose uptake was examined in vivo over a 30 min period (A).
Additionally, cardiac glucose uptake (B), lactate production (C) and tissue lactate concentration (D) were measured directly in the Langendorff
perfused hearts. Values are presented as mean 6 SEM. *p,0.05 vs. vehicle.
doi:10.1371/journal.pone.0023570.g002
Cardioprotection by Albiglutide
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hearts, several genes associated with glycolysis and glycogenesis
(ALDOC, CPT1B, IGF1R, PDHA1, GSK3B, GYS1, SLC2A1)
increased significantly in the non-ischemic region of the I/R hearts
following treatment with albiglutide. Principal Component
Analysis (PCA) of the gene expression data collected from all
three heart tissue samples suggests clustering of both normal (non-
infarcted hearts) and area not at risk (infarcted hearts) tissue
expression data following treatment with albiglutide, which is
consistent with a definite alteration in regulation of glucose and fat
metabolism genes in both normal and non-ischemic regions of the
heart (Figure 5).
Cardiac energetics
Cardiac MRI was used to assess LV function at 24 h post-I/R
injury. Although the vehicle-treated rats had significantly reduced
LV ejection fractions and increased LV end systolic volumes
compared to sham, albiglutide treatment prevented the deleterious
cardiac remodeling and function decline (Figure 6A, B).
31P MRS
spectra from sham, vehicle-and albiglutide-treated hearts are
presented in Figure 6C with the prominent high-energy phosphate
peaks labeled (i.e., c-ATP at 22.4 ppm, a-ATP at 27.5 ppm,
bATP at 216 ppm, PCr at 0 ppm, and Pi at 4.9–5.1 ppm). As a
result of I/R injury, the PCr peak is visibly decreased and Pi peak
increased at the expense of maintaining steady state ATP
concentrations via the creatine kinase enzyme reaction. The
PCr/ATP ratio was variable and while it appeared to be lower in
the vehicle group, the trend was not significant (Figure 6D).
However, whereas the PCr/Pi ratio and the cellular pH were
decreased in the vehicle group vs. sham (p,0.05), albiglutide
prevented a change in these parameters (Figure 6E, F, respective-
ly). Additionally, absolute whole heart ATP and PCr concentra-
tions were markedly lower in vehicle-treated hearts compared to
sham and albiglutide-treated hearts. (Figure 6G, H).
Discussion
In the present study, it was demonstrated for the first time that
albiglutide reduces myocardial infarct size in the experimental
setting of acute myocardial I/R injury. The cardioprotective effect
of albiglutide was further confirmed by the enhancement of post-
ischemic cardiac function and energetic profile. In addition,
assessment of [
3H]-2-deoxyglucose uptake in vivo revealed that
albiglutide markedly increased cardiac glucose uptake. Further-
more, in the Langendorff perfused heart, albiglutide exhibited an
insulinomimetic effect by directly increasing cardiac glucose
uptake and decreasing lactate efflux. The decreased lactate efflux
was also associated with a direct increase in lactate oxidation
which ultimately reflected a shift in cardiac metabolic substrate
utilization with albiglutide that increased the relative carbohydrate
oxidation versus fat oxidation. These results indicate that the
infarct size-limiting effect of albiglutide was associated with an
increase in glucose disposal, an increase in aerobic glycolysis, and
an increase in lactate oxidation which resulted in an improved
cardiac energetic state. These findings suggest that in addition to
providing peripheral glycemic control, albiglutide may have direct
therapeutic potential for improving cardiac function in the setting
of myocardial ischemic injury.
Albiglutide exhibited acute pharmacological effects consistent
with the systemic activation of the GLP-1 receptor [29]. These
effects include body weight loss, reduced food intake, increased
insulin secretion and reduced blood glucose following treatment.
Treatment in the present study was initiated two days prior to
myocardial ischemia as it was determined that albumin was
maximally equilibrated with the heart after 48 hrs and conse-
quently cardiac albiglutide exposure is greatest at this time (data
not shown). Therefore, it is not known whether cardioprotection
could be rendered if therapeutic dosing was initiated post-
ischemia. Further investigation is necessary in order to address
the potential for this therapeutic paradigm with albiglutide. In
addition, the cardioprotection was observed with plasma concen-
trations as low as 17 nM which is within the pharmacological
dosing range in type 2 diabetic patients in the clinic [16].
Myocardial infarct size is the gold standard for assessing
myocardial I/R injury. Numerous studies examining the cardio-
protective benefit of GLP-1 [4–7], exentatide [7,9] and liraglutide
[10] in models of I/R have been performed. As in the case of our
study the cardioprotection observed with these GLP-1 agents was
Figure 3. In vivo intermediary glucose metabolism in normal rat hearts. A euinsulinemic-hyperglycemic clamp was performed for 2 h using
1-
13C glucose as the exogenous precursor. LV intermediary metabolite
13C enrichments of alanine, lactate, and glutamate are presented as atom
percent excess (APE) (A). The intermediary metabolite enrichments were used to indirectly assess the relative metabolic flux through carbohydrate
versus fat oxidation as a percentage of flux through acetyl-CoA (B). Values are presented as mean 6 SEM. *p,0.05 vs. vehicle.
doi:10.1371/journal.pone.0023570.g003
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presence of a DDP-IV inhibitor has been shown to be beneficial in
therapeutic mode (i.e. administration of drug post-infarct) [4].
Additionally, a few large animal cardioprotection studies using
GLP-1 and mimetics in dog [13] and pig [9,11] have been
performed. While the evidence is clear that treatment with GLP-1
or mimetic prior to ischemic insult renders cardioprotection in
rodents, there have been conflicting results in these larger animal
studies. The study by Kristensen et al. [11] showed that pre-
ischemic administration of liraglutide for 3 days prior to ischemic
insult did not result in cardioprotection in the pig. Importantly,
infarct size was measured 2.5 h after reperfusion in that study,
whereas infarct size was determined 24 h post-reperfusion in the
present study. Previous studies indicate that reperfusion time
affects myocardial infarct size measurements [30,31]. It is possible
that the different experimental protocol such as reperfusion time
could account for the negative outcome observed in the liraglutide
study. In the current study, the area at risk was comparable
between vehicle- and albiglutide-treated rats suggesting that all the
animals were subjected to a similar ischemic insult. In addition,
recombinant human albumin alone at a dose of 2.7 mg/kg was
administered to the rats as a control experiment without having
any effect on myocardial infarct size (data not shown), further
confirming the infarct size-limiting effect of albiglutide.
The cardioprotective effect of albiglutide was further confirmed
by improvements in cardiac function post-ischemia. The elevation
of left ventricular end-diastolic pressure and reduction in left
ventricular contractility, as assessed by dP/dtmax, induced by
ischemia/reperfusion injury were blunted with albiglutide. Addi-
tionally, LV ejection fraction and ESV were normalized. The
improvement in post-ischemic cardiac function by albiglutide may
be via a direct inotropic effect on the heart with activation of GLP-
1 receptor in the setting of cardiac dysfunction [7,14,32], or via an
indirect effect secondary to its reduction in myocardial infarct size.
However, albiglutide exhibited no direct inotropic effect in control
animals (data not shown). Indeed, reports showing the direct
insulinomimetic effects of GLP-1 in both rodent perfused hearts
[6,7,32], as well as in chronically instrumented dogs [13,14], argue
that an increase in glucose metabolism via direct insulinomimetic
actions or via an indirect insulinotropic mechanism may in large
part promote the cardioprotection afforded by GLP-1 receptor
agonists. While albiglutide did reflect increased glucose uptake in
perfused hearts and in insulin clamped hearts, in vivo, suggesting
an insulinomimetic effect, one cannot rule out the possibility that
the heart was predisposed to insulin sensitization upon two days of
albiglutide treatment prior to the glucose disposal measurement.
GLP-1 was previously shown to increase cardiac lactate efflux
concomitant with increased glucose disposal [6]. Albiglutide
treatment resulted in a similar systemic elevation of plasma lactate
at the high doses, although within the physiological range. This
effect may be a result of the increased glucose disposal and
glycolytic production of lactate by peripheral insulin sensitive
tissue as plasma glucose was significantly reduced with albiglutide.
Surprisingly, local lactate efflux in the heart was reduced following
albiglutide treatment. Additionally, cardiac tissue lactate concen-
tration was reduced with albiglutide along with the reduced lactate
efflux and increased lactate oxidation. The consequence of this
finding may be that there was decreased anaerobic glycolysis
under conditions of increased glucose utilization with albiglutide.
Perhaps tighter aerobic coupling of glucose oxidation was present.
The increase in lactate oxidation observed in the albiglutide
treated isolated hearts also confirms that the aerobic coupling of
carbohydrate substrate oxidation was active. The heart, under
normal conditions, oxidizes lactate [33]; however, following
ischemic stress, the heart becomes a net producer of lactate [6]
with intracellular lactate concentrations increasing significantly.
This may be deleterious in a diabetic population where lactate
acidosis is a significant liability not only peripherally, but also
directly in the heart [34]. Our study indicates that albiglutide may
be able to resolve these deleterious effects, but future cardiopro-
tection studies in diabetic animal models are warranted.
Interestingly, although albiglutide promotes cardiac glucose
uptake, the cardiac glycogen concentration was not increased in
albiglutide-treated hearts, consistent with the notion that albigu-
tide did not promote glycogenesis but increased cardiac glycolysis
and glucose oxidation. Analysis of intermediary substrate handling
as assessed by using a 1-
13C glucose clamp allowed differentiation
between carbohydrate oxidation (e.g. glucose, lactate, and
pyruvate) and FFA oxidation by examining the degree of 4-
13C
glutamate enrichment dilution from unlabeled FFA [24–26].
Figure 4. Lactate disposition ex vivo. Net lactate efflux across the
heart during a 30 min perfusion period using a 1 mM 3-
13C lactate
precursor (A), cardiac tissue lactate concentration (B), and relative
lactate oxidation as reflected by increased glutamate labeling (C).
Values are presented as mean 6 SEM. *p,0.05 vs. vehicle.
doi:10.1371/journal.pone.0023570.g004
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between vehicle- and albiglutide-treated hearts, but glutamate
enrichment was significantly greater in albiglutide-treated hearts,
reflecting that albiglutide increased carbohydrate versus fat
oxidation in the heart and providing further evidence for the
beneficial effect of increasing oxidative glucose handling in these
hearts. A switch in myocardial substrate utilization from FFA
towards glucose would provide an oxygen-sparing effect of
approximately 12% for the same amount of ATP production
[35]. This change in substrate utilization could provide the heart
protective benefits in the setting of myocardial ischemic injury or
possibly in the setting of the chronic dilated cardiomyopathy
where impaired cardiac glucose metabolism and a reduced
energetic state have also been observed [36,37]. However, it is
possible that other potential cardioprotective mechanisms such as
anti-apoptosis via AKT signaling, and/or activation of RISK
pathways may be contributing to the observed cardioprotection
[4,9]. Indeed, albiglutide significantly upregulated genes associated
with cell survival such as IGF-1R, HIF-1a and AKT.
This more favorable energetic profile was substantiated by
examining the high energy phosphate profile in the heart following
I/R insult. There was a significant increase in the PCr/Pi ratio
and ATP concentration in the area at risk in hearts treated with
albiglutide. In addition, the reduction in pH following I/R injury
was abrogated with albiglutide reflecting reduced anaerobic
glycolysis which could lead to improved contractility [38]. The
lack of benefit observed in the PCr/ATP ratio was most likely due
to the decreased ATP concentration in the ischemic area of the
vehicle group. The metabolic profile that was exhibited in
albiglutide-treated hearts was also consistent with the altered gene
expression profile observed in normal heart or non-ischemic heart
following I/R injury as reflected by principal component analysis.
This finding is a possible reflection of the ability of albiglutide to
affect the metabolic profile and efficiency which ultimately
translates to increased contractile efficiency in the adjacent border
Table 3. Effect of albiglutide on metabolic gene
transcriptional changes in the heart.
GENE Gene Name
Albiglutide
vs. Vehicle
(fold change) p Value
ACSL1 Acetyl CoA Synthase 1 1.42 0.0003
CPT1B Carnitine Palmitoyltransferase
1B (muscle)
1.44 0.0004
GAPDH Glyceraldehyde 3-Phosphate
Dehydrogenase
1.24 0.0004
IGF1R Insulin Growth Factor 1R 1.36 0.0005
SLC2A4 Glucose Transporter 4 1.34 0.0006
HK2 Hexokinase 2 1.41 0.0007
GYS1 Glycogen Synthase 1.21 0.0012
ESSRA Estrogen Receptor,
alpha isoform
1.29 0.0022
HIF1A HIF-1 a 1.22 0.0045
PPARGC1A PGC-1a 1.28 0.0085
PDHA1 Pyruvate Dehydrogenase 1.17 0.0116
ALDOC Fructose 1, 6
Bisphosphate Aldolase
1.36 0.0120
GSK3B Glycogen Synthase Kinase 1.16 0.0378
AKT1 AKT1 1.13 0.0413
SLC2A1 Glucose Transporter 1 1.24 0.0570
PYGL Glycogen Phosphorylase 21.33 0.1158
PRKAA2 AMPK 1.06 0.1820
PPARG PPAR Gamma 1.12 0.1862
HK1 Hexokinase 1 1.06 0.2117
PDK1 Pyruvate Dehydrogenase
Kinase
1.28 0.2247
UCP2 Uncoupling Protein 2 1.16 0.4040
ACTB b- Actin 1.03 0.6339
LDHA Lactate Dehydrogenase-1
(LDH-1)
1.02 0.7039
UCP3 Uncoupling Protein 3 21.04 0.8503
Gene transcription regulation in albiglutide vs. vehicle treated hearts. Data are
presented as fold change vs. vehicle, n=8 per group.
doi:10.1371/journal.pone.0023570.t003
Figure 5. Principal Component Analysis of metabolic genes.
Principal Component Analysis of the gene expression data collected
from normal and ischemia injured heart samples was performed and
presented for normal hearts (A) and area at risk hearts following 30 min
myocardial ischemia and 24 h reperfusion (B) and area not at risk hearts
from the same animals (C).
doi:10.1371/journal.pone.0023570.g005
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cardiac energetic and function in the heart while only reducing the
infarct size by ,26% suggests that there was a significant energetic
and contractile benefit of albiglutide in the non-ischemic LV.
In summary, albiglutide, a novel GLP-1 analog with a long half-
life, reduced myocardial infarct size and improved post-ischemic
cardiac function and energetics following myocardial I/R injury.
The observed benefits were associated with enhanced myocardial
glucose uptake and shift toward a more energetically favorable
substrate metabolism profile by increasing both glucose and lactate
oxidation. These findings suggest that in addition to providing
peripheral glycemic control, albiglutide may have direct thera-
peutic potential for improving cardiac energetic and function in
the setting of myocardial ischemic injury.
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